Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia

NCT07432100 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Chimeric Antigen Receptor T-cell
Universal CLL1 CAR-T

Interventions

BIOLOGICAL: universal CLL1 CAR-T cells

Sponsor

Mingfeng Zhao